(Total Views: 753)
Posted On: 01/10/2022 5:13:05 PM
Post# of 153911
In regards to Regnum -
1. Shkreli was supposed to turn over all his Phoenixus shares over a year ago and is barred from owning pharmaceutical company stock. So he should be out of the picture.
2. Most likely being done to protect assets.
3. It affects Cytodyn very little. It only pertains to HIV which in the long run will only be a small percentage of overall sales of leronlimab. If Regnum can pay their milestone payments and effectively market leronlimab then no problem. If it can't the contract is null and void and Cytodyn regains control of distribution.
1. Shkreli was supposed to turn over all his Phoenixus shares over a year ago and is barred from owning pharmaceutical company stock. So he should be out of the picture.
2. Most likely being done to protect assets.
3. It affects Cytodyn very little. It only pertains to HIV which in the long run will only be a small percentage of overall sales of leronlimab. If Regnum can pay their milestone payments and effectively market leronlimab then no problem. If it can't the contract is null and void and Cytodyn regains control of distribution.
(8)
(0)
